6E62

Crystal structure of malaria transmission-blocking antigen Pfs48/45 6C in complex with antibody 85RF45.1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.70 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.246 
  • R-Value Observed: 0.247 

wwPDB Validation 3D Report Full Report



Literature

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.

Kundu, P.Semesi, A.Jore, M.M.Morin, M.J.Price, V.L.Liang, A.Li, J.Miura, K.Sauerwein, R.W.King, C.R.Julien, J.P.

(2018) Nat Commun 9: 4458-4458

  • DOI: 10.1038/s41467-018-06742-9
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Interventions that can block the transmission of malaria-causing Plasmodium falciparum (Pf) between the human host and Anopheles vector have the potential to reduce the incidence of malaria. Pfs48/45 is a gametocyte surface protein critical for paras ...

    Interventions that can block the transmission of malaria-causing Plasmodium falciparum (Pf) between the human host and Anopheles vector have the potential to reduce the incidence of malaria. Pfs48/45 is a gametocyte surface protein critical for parasite development and transmission, and its targeting by monoclonal antibody (mAb) 85RF45.1 leads to the potent reduction of parasite transmission. Here, we reveal how the Pfs48/45 6C domain adopts a (SAG1)-related-sequence (SRS) fold. We structurally delineate potent epitope I and show how mAb 85RF45.1 recognizes an electronegative surface with nanomolar affinity. Analysis of Pfs48/45 sequences reveals that polymorphisms are rare for residues involved at the binding interface. Humanization of rat-derived mAb 85RF45.1 conserved the mode of recognition and activity of the parental antibody, while also improving its thermostability. Our work has implications for the development of transmission-blocking interventions, both through improving vaccine designs and the testing of passive delivery of mAbs in humans.


    Organizational Affiliation

    Departments of Biochemistry and Immunology, University of Toronto, Toronto, M5S 1A8, ON, Canada. jean-philippe.julien@sickkids.ca.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Pf48/45
A, P
139Plasmodium falciparumMutation(s): 0 
Find proteins for Q8I6T1 (Plasmodium falciparum (isolate 3D7))
Go to UniProtKB:  Q8I6T1
Protein Feature View
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
85RF45.1 Fab heavy chain
B, H
222Rattus norvegicusMutation(s): 0 
Protein Feature View
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
85RF45.1 Fab light chain
C, L
216Rattus norvegicusMutation(s): 0 
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NAG
Query on NAG

Download CCD File 
A, P
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
GOL
Query on GOL

Download CCD File 
B, H
GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.70 Å
  • R-Value Free: 0.276 
  • R-Value Work: 0.246 
  • R-Value Observed: 0.247 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 54.51α = 90
b = 74.45β = 90
c = 321.89γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Bill & Melinda Gates FoundationUnited StatesOPP1108403

Revision History 

  • Version 1.0: 2018-11-28
    Type: Initial release